Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (DOSE-HEP)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by South West Sydney Local Health District.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
South West Sydney Local Health District
Information provided by:
South West Sydney Local Health District
ClinicalTrials.gov Identifier:
NCT01078311
First received: March 1, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Sorafenib improves overall survival and progression free survival in advanced hepatocellular carcinoma. Wide interindividual pharmacokinetic variability was observed. Data from early phase trials in solid tumours showed trough sorafenib levels were associated with incidence of skin rash and hypertension. Rash, hypertension and higher trough levels were moderately predictive of progression free survival.The trough level of sorafenib may be predictive of survival and response in patients treated with sorafenib for advanced hepatocellular carcinoma.
| Condition |
|---|
|
Hepatocellular Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Phase 2 Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
Resource links provided by NLM:
Further study details as provided by South West Sydney Local Health District:
Primary Outcome Measures:
- To demonstrate the correlation of trough sorafenib level with overall survival in advanced hepatocellular carcinoma [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To correlate trough sorafenib level with progression free survival [ Time Frame: 4 years ] [ Designated as safety issue: No ]
- To correlate trough sorafenib level with response (disease-control vs progressive disease) by RECIST criteria [ Time Frame: 4 years ] [ Designated as safety issue: No ]
- To correlate trough sorafenib level with alpha fetoprotein (AFP) response [ Time Frame: 4 years ] [ Designated as safety issue: No ]
- To correlate trough sorafenib level with side effects (rash and hypertension) [ Time Frame: 4 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| HCC patients on Sorafenib |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients with advanced HCC who are to commence Sorafenib
Criteria
Inclusion Criteria:
- ECOG ≤ 2
- Histologically or cytologically diagnosed hepatocellular carcinoma, or diagnosis on at least one cross-sectional imaging with the characteristic appearance of HCC (i.e. liver lesion with arterial enhancement and portal venous washout)
- Decision to treat with single agent sorafenib at 400mg bid (dose reductions or interruptions are permitted if side effects occur during treatment)
- No prior systemic chemotherapy or targeted therapy
- Child-Pugh liver function class A or B
- At least one untreated target lesion that can be measured in one dimension according to RECIST
- Adequate organ functions
Exclusion Criteria:
- Prior systemic chemotherapy or molecularly targeted therapy
- Concurrent active malignancy
- Concomitant strong CYP3A4 induced or inhibitor at a therapeutic dose (see section 6.4.1)
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent
- Hypertension that cannot be controlled by medications (> 150/100 mmHg despite optimal medical therapy)
- History of, or known brain metastases (skull metastases allowed), carcinomatous meningitis, or leptomenigeal disease
- Major surgery (e.g. open abdominal therapy, pelvic, thoracic, orthopaedic or neurosurgery) within 4 weeks of the date of first dose
- Local-regional treatment (i.e. percutaneous and trans-arterial procedures) within 4 weeks. Restaging CT or MRI scan must be repeated at least 4 weeks after local-regional treatment and within 3 weeks before the date of first dose
- For patients treated with Yttrium (90Y) radiotherapy, a washout period of 2 months is required.
- Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol
- Pregnancy or breast feeding
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01078311
Please refer to this study by its ClinicalTrials.gov identifier: NCT01078311
Contacts
| Contact: Mark Wong, MBBS, FRACP | 61298455200 ext 55200 | Mark.Wong@swahs.health.nsw.gov.au |
Locations
| Australia, New South Wales | |
| Westmead Hospital | Recruiting |
| Westmead, New South Wales, Australia, 2145 | |
Sponsors and Collaborators
South West Sydney Local Health District
More Information
| Responsible Party: | Mark Wong, Westmead Medical Oncology |
| ClinicalTrials.gov Identifier: | NCT01078311 History of Changes |
| Other Study ID Numbers: | MWWH009 |
| Study First Received: | March 1, 2010 |
| Last Updated: | March 1, 2010 |
| Health Authority: | Australia:SWAHS Human Research Ethics Committee |
Keywords provided by South West Sydney Local Health District:
|
Patients with advanced hepatocellular cancer |
Additional relevant MeSH terms:
|
Carcinoma, Hepatocellular Liver Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Liver Diseases Sorafenib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on September 30, 2016